ドラベ症候群：市販薬・パイプライン薬の評価、臨床試験、ソーシャルメディア、競合情勢-2022年最新版

2022年の16の医薬品市場において、ドラベ症候群の有病者数は12万3,000人以上となる見込みです。ドラベ症候群のパイプラインは、すべての開発段階にまたがる38の医薬品で構成されており、90%以上が初期開発段階にあります。臨床試験開発は商業スポンサーが中心となっており、米国は臨床試験を実施する主要国として浮上しています。

当レポートは、ドラベ症候群について調査分析し、病気の情勢、市販薬・パイプライン薬の評価、臨床試験の評価、取引情勢に関する情報を提供しています。

目次

目次

第1章 序文

• コンテンツ
• 調査範囲
• 図表リスト
• 略語

第2章 重要な調査結果

第3章 病気の情勢

• 病気の概要
• 疫学の概要
• 治療の概要

第4章 市販薬の評価

• 主要な市販薬
• 概要：作用機序別
• 概要：投与経路別
• 概要：分子タイプ別
• 市販薬のプロファイルと売上予測

第5章 パイプライン薬の評価

• 後期パイプライン薬
• 概要：開発段階別
• 概要：作用機序別
• 概要：投与経路別
• 概要：分子タイプ別
• 薬剤固有の相転移成功率（PTSR）と承認の可能性（LoA）
• 治療領域と適応症別のPTSRおよびLoA

第6章 臨床試験の評価

• 過去の概要
• 概要：フェーズ別
• 概要：ステータス別
• 概要：進行中および計画中の試験のフェーズ別
• 仮想コンポーネントを使用した試行
• 地理的概要
• 単一国および多国間共同試験：地域別
• 上位20のスポンサーと内訳：フェーズ別
• 上位20のスポンサーと内訳：ステータス別
• 概要：エンドポイントステータス別
• 概要：人種および民族別
• 登録データ
• トライアルサイトの上位20か国
• 世界の上位20サイト
• 実現可能性分析-地理的概要
• 実現可能性分析-ベンチマークモデル

第7章 取引情勢

• 合併、買収、戦略的提携：地域別
• 最近の合併、買収、戦略的提携

第8章 商業的評価

• 市場の主要企業

第9章 将来の市場カタリスト

第10章 付録

• 調査手法
• 調査手法-PTSRおよびLoA分析
• 著者について
• お問い合わせ
• 免責事項

This reports provides a data-driven overview of the current and future competitive landscape in Dravet Syndrome therapeutics.

Synopsis

• In 2022, there will be more than 123,000 diagnosed prevalent cases of Dravet syndrome across 16 pharmaceutical markets.
• Two FDA-approved branded marketed drugs are available for the treatment of Dravet syndrome.
• The Dravet syndrome pipeline consists of 38 pharmaceuticals spanning all stages of development, with more than 90% of drugs in early-stage development.
• Commercial sponsors dominate clinical trial development in Dravet syndrome, with the US emerging as the key country for conducting trials in Dravet syndrome.
• Deals involving licensing and partnership for Dravet syndrome assets are the most common types of deals globally.
• Companies are increasingly focusing on R&D activities to develop anti-epileptic drugs (AEDs) with novel mechanisms of action.

Scope

GlobalData's Dravet Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Dravet Syndrome market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Dravet Syndrome market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Overview by Molecule Type
• 4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

• 5.1 Late-stage Pipeline Drugs
• 5.2 Overview by Development Stage
• 5.3 Overview by Mechanism of Action
• 5.4 Overview by Route of Administration
• 5.5 Overview by Molecule Type
• 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

• 6.1 Historical Overview
• 6.2 Overview by Phase
• 6.3 Overview by Status
• 6.4 Overview by Phase for Ongoing and Planned Trials
• 6.5 Trials with Virtual Components
• 6.6 Geographic Overview
• 6.7 Single-Country and Multinational Trials by Region
• 6.8 Top 20 Sponsors with Breakdown by Phase
• 6.9 Top 20 Sponsors with Breakdown by Status
• 6.10 Overview by Endpoint Status
• 6.11 Overview by Race and Ethnicity
• 6.12 Enrollment Data
• 6.13 Top 20 countries for Trial Sites
• 6.14 Top 20 Sites Globally
• 6.15 Feasibility Analysis - Geographic Overview
• 6.16 Feasibility Analysis - Benchmark Models

7 Deals Landscape

• 7.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

• 8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

• 10.1 Methodology
• 10.2 Methodology - PTSR and LoA Analysis
• 10.3 About the Authors
• 10.4 Contact Us
• 10.5 Disclaimer